DMTK vs. PMD, BGLC, XGN, RNLX, OPGN, COEP, IKT, PSTV, DOMH, and ELAB
Should you be buying DermTech stock or one of its competitors? The main competitors of DermTech include Psychemedics (PMD), BioNexus Gene Lab (BGLC), Exagen (XGN), Renalytix (RNLX), OpGen (OPGN), Coeptis Therapeutics (COEP), Inhibikase Therapeutics (IKT), Plus Therapeutics (PSTV), Dominari (DOMH), and Elevai Labs (ELAB).
DermTech (NASDAQ:DMTK) and Psychemedics (NASDAQ:PMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk.
DermTech presently has a consensus price target of $2.38, suggesting a potential upside of 554.73%. Given DermTech's higher possible upside, equities analysts clearly believe DermTech is more favorable than Psychemedics.
20.5% of DermTech shares are owned by institutional investors. Comparatively, 32.1% of Psychemedics shares are owned by institutional investors. 5.1% of DermTech shares are owned by company insiders. Comparatively, 24.0% of Psychemedics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, DermTech and DermTech both had 2 articles in the media. DermTech's average media sentiment score of 1.88 beat Psychemedics' score of 1.87 indicating that DermTech is being referred to more favorably in the media.
Psychemedics received 96 more outperform votes than DermTech when rated by MarketBeat users. Likewise, 74.35% of users gave Psychemedics an outperform vote while only 57.50% of users gave DermTech an outperform vote.
DermTech has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500. Comparatively, Psychemedics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
Psychemedics has higher revenue and earnings than DermTech. Psychemedics is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.
Psychemedics has a net margin of -20.23% compared to DermTech's net margin of -572.19%. Psychemedics' return on equity of -59.21% beat DermTech's return on equity.
Summary
Psychemedics beats DermTech on 10 of the 15 factors compared between the two stocks.
Get DermTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DMTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DermTech Competitors List
Related Companies and Tools
